Compare Quest Diagnostics Inc (DGX) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Eos Energy Enterprises Inc — how do they compare? Quest Diagnostics Inc trades at $230.04 (market cap $25.48B), while Eos Energy Enterprises Inc trades at $2.78 (market cap $1.01B). The key difference: Quest Diagnostics Inc is far larger — about 25.2× Eos Energy Enterprises Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Eos Energy Enterprises Inc for 16 Days on average.
| DGX | EOSE | |
|---|---|---|
Market Cap | $25.48B | $1.01B |
Volume | 941,866 | 39,626,541 |
Sector | Health | Industrials |
52-Week High | $247.45 | $19.19 |
52-Week Low | $173.49 | $2.77 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $31.23B | $1.34B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% today, amid a bearish technical signal. The company is in a high-growth phase, with revenue surging from $114 million in 2025 to $214 million in 2026, but it remains deeply unprofitable, with a net income margin of -246.76% in 2026. Recent positive developments include a major partnership with Google for a $350 million West Virginia project and an $87 million Department of Energy loan advance to expand manufacturing capacity.
The outlook is a high-risk, high-reward proposition. Significant revenue growth and strategic partnerships offer substantial upside potential, with a consensus price target of $7.10. However, persistent negative cash flow from operations, high debt-to-asset ratio of 91.87%, and intense competition in the energy storage sector pose severe risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
